Opendata, web and dolomites

RetinDR SIGNED

RetinDR: The first topical ophthalmic formulation (eye drops) that effectively prevents and/or treats the retinal neurodegeneration induced by diabetes (diabetic retinopathy) and/or aging

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RetinDR project word cloud

Explore the words cloud of the RetinDR project. It provides you a very rough idea of what is the project "RetinDR" about.

quite    grow    successful    115       aging    drug    treats    neurodegeneration    diabetic    sme    pharmaceutical    jobs    wacc    double    81b    reading    progresses    endothelin    arterial    aged    people    indicated    till    forecast    model    repurposing    aggressive    million    prevents       bosentan    estimate    company    usually    topical    52m    commercialisation    receptor    substance    suffer    licensing    sales    2025    retinal    symptoms    outside    strategic    considering    equalling    seeing    npv    ophthalmic    blurred    ebitda    dr    cagr    share    stages    vision    antagonist    business    pulmonary    55m    agreements    disease    spots    accounted    98       plan    europeans    21m    2016    market    formulation    royalties    limited    difficulty    global    22    treatment    eye    commercialization    hypertension    receive    completion    blindness    treatments    adults    diabetes    parent    prevention    floaters    final    medical    worldwide    co    93    markets    feasibility    industrial    effectiveness    retindr    peripheral    drops    15    irr    revenues    retinopathy    mix    months   

Project "RetinDR" data sheet

The following table provides information about the project.

Coordinator
RETINSET SL 

Organization address
address: AMPOSTA 20
city: SANT CUGAT DEL VALLES
postcode: 8174
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RETINSET SL ES (SANT CUGAT DEL VALLES) coordinator 50˙000.00

Map

 Project objective

Diabetic retinopathy (DR) is the leading cause of blindness among working-aged adults. About 93 million people worldwide and 3%-4.1% of Europeans suffer this disease. The early stages of DR usually have no symptoms, however when the disease progresses it affects vision: blurred vision, seeing double, difficulty reading, spots or floaters in the field of vision, and loss of peripheral vision. Current treatments are quite aggressive, are only indicated in advanced stages of the disease, have significant side effects and their effectiveness is limited. RetinDR is a topical ophthalmic formulation (eye drops) that effectively prevents and/or treats the retinal neurodegeneration induced by diabetes (diabetic retinopathy) and/or aging. The pharmaceutical development of RetinDR is based on the repurposing of the drug substance bosentan (endothelin receptor antagonist, currently indicated for the pulmonary arterial hypertension treatment) for the prevention and treatment of DR.

The global DR market accounted for $5.81B in 2016 and is forecast to grow at 6.3%. CAGR till 2025. We estimate a market share of 0.115% 5 years after commercialisation, equalling revenues of 52M€. Our main business model will focus on sales and distribution of RetinDR in Europe through a distribution agreement with the parent company Medical Mix S.L. and co-development or licensing agreements with strategic industrial partners in markets outside of Europe where we will receive royalties.

With this model and the successful completion of the SME Phase 1 and 2 we estimate an EBITDA of over 55M€ in 5 years after commercialization an IRR of 98% and NPV of over 21M€ considering a WACC of 15%, creating 22 new jobs by 2025. The Feasibility Study for this project will take 6 months and focus on an in-depth market study, technical testing and the development of final business plan to take us to market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RETINDR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RETINDR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Presque (2019)

Smart Nursing Bra

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

PAROST (2019)

Disruptive technology for the identification, quantification and prediction of the evolution of damages in civil engineering structures that increases safety while reducing maintenance costs.

Read More